Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00005852 |
Date of registration:
|
02/06/2000 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
|
Scientific title:
|
Allogeneic Bone Marrow Transplantation for Marrow Failure States |
Date of first enrolment:
|
June 1996 |
Target sample size:
|
|
Recruitment status: |
Terminated |
URL:
|
http://clinicaltrials.gov/show/NCT00005852 |
Study type:
|
Interventional |
Study design:
|
Primary Purpose: Treatment
|
Phase:
|
Phase 2
|
|
Contacts
|
Name:
|
Steven C. Goldstein, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
H. Lee Moffitt Cancer Center and Research Institute |
| | |
Key inclusion & exclusion criteria
|
DISEASE CHARACTERISTICS: Histologically confirmed aplastic anemia Must have related donor
with a genotypic 6 out of 6 HLA A, B, and DR match OR Bone marrow transplant failure Must
have related donor with at least a 5 out of 6 HLA match OR Must have an unrelated donor
with at least a 5 out of 6 HLA match
PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: Aplastic anemia patients:
Karnofsky 80-100% Graft failure patients: Karnofsky 20-100% Life expectancy: Not specified
Hematopoietic: See Disease Characteristics Hepatic: Aplastic anemia patients: Bilirubin no
greater than 2.0 mg/dL SGOT/SGPT no greater than 3 times normal PT/PTT normal (except when
aplastic anemia secondary to viral hepatitis) Graft failure patients: Mild to severe
venoocclusive disease allowed Renal: Aplastic anemia patients: Creatinine no greater than
2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: Aplastic anemia
patients: Left ventricular ejection fraction at least 45% by MUGA or echocardiography No
myocardial infarction within the past 6 months No uncontrolled arrhythmias Pulmonary:
Aplastic anemia patients: FEV1 and DLCO at least 50% predicted Other: Aplastic anemia
patients: No uncontrolled diabetes mellitus or thyroid disease No active serious
infections HIV negative Not pregnant or nursing Negative pregnancy test No psychosocial
problem that would preclude study compliance
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not
specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
specified
Age minimum:
15 Years
Age maximum:
55 Years
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Multiple Myeloma and Plasma Cell Neoplasm
|
Leukemia
|
Chronic Myeloproliferative Disorders
|
Graft Versus Host Disease
|
Myelodysplastic Syndromes
|
Lymphoma
|
Intervention(s)
|
Procedure: allogeneic bone marrow transplantation
|
Biological: anti-thymocyte globulin
|
Biological: filgrastim
|
Drug: cyclophosphamide
|
Drug: cyclosporine
|
Biological: muromonab-CD3
|
Drug: methylprednisolone
|
Secondary ID(s)
|
MCC-IRB-4251
|
NCI-G00-1791
|
MCC-11309
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|